Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Lucija Hok, Hrvoje Rimac, Janez Mavri, Robert Vianello
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local citing links have been materialized yet.
COVID-19 pandemic: perspectives on an unfolding crisis
10.1002/bjs.11627 · 2020
10.1016/s1473-3099(20)30120-1
10.1016/s1473-3099(20)30120-1
10.1016/j.clim.2020.108427
10.1016/j.clim.2020.108427
The socio-economic implications of the coronavirus pandemic (COVID-19): A review
10.1016/j.ijsu.2020.04.018 · 2020
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
10.1016/s2215-0366(21)00084-5 · 2021
10.1016/s1474-4422(20)30221-0
10.1016/s1474-4422(20)30221-0
10.1001/jamaneurol.2020.2065
10.1001/jamaneurol.2020.2065
10.1002/mds.28084
10.1002/mds.28084
10.1111/ene.14277
10.1111/ene.14277
10.1038/s41586-020-2012-7
10.1038/s41586-020-2012-7
10.1002/path.1570
10.1002/path.1570
10.1021/acscentsci.0c01056
10.1021/acscentsci.0c01056
An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19
10.1002/jmv.25826 · 2020
10.1148/radiol.2020201187
10.1148/radiol.2020201187
10.1093/infdis/jiv499
10.1093/infdis/jiv499
10.1007/s12035-020-02245-1
10.1007/s12035-020-02245-1
SARS-CoV-2 (COVID-19) as a Predictor of Neuroinflammation and Neurodegeneration: Potential Treatment Strategies
10.1007/s11055-021-01108-z · 2021
Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration
10.1007/s12035-020-02236-2 · 2021
10.1016/j.neuropharm.2019.02.008
10.1016/j.neuropharm.2019.02.008
Toll-like receptors and COVID-19: a two-faced story with an exciting ending
10.2144/fsoa-2020-0091 · 2020
10.1021/acs.jpcb.0c04317
10.1021/acs.jpcb.0c04317
10.1021/acs.jpclett.0c01148
10.1021/acs.jpclett.0c01148
10.3390/v12010014
10.3390/v12010014
10.1016/j.bbi.2020.03.031
10.1016/j.bbi.2020.03.031
Impact of coronavirus outbreak on psychological health
10.7189/jogh.10.010331 · 2020
The stressful life events and Parkinson's disease: a case-control study
10.1002/smi.2424 · 2013
10.1007/s00702-018-1881-5
10.1007/s00702-018-1881-5
10.1002/9781119245544.ch8
10.1002/9781119245544.ch8 · 2017
10.1001/archpsyc.63.11.1209
10.1001/archpsyc.63.11.1209
10.1016/j.jchemneu.2021.101957
10.1016/j.jchemneu.2021.101957
10.1016/j.arr.2021.101256
10.1016/j.arr.2021.101256
Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson’s Disease
10.3389/fncel.2021.670298 · 2021
Are dopamine and serotonin involved in COVID-19 pathophysiology?
10.1016/j.ejpsy.2020.10.004 · 2021
10.3390/healthcare8030286
10.3390/healthcare8030286
COVID-19: dealing with a potential risk factor for chronic neurological disorders
10.1007/s00415-020-10131-y · 2021
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection
10.1038/s41598-021-90243-1 · 2021
10.1016/j.cell.2020.05.032
10.1016/j.cell.2020.05.032
10.1038/s41586-020-2180-5
10.1038/s41586-020-2180-5
10.1126/science.abb2762
10.1126/science.abb2762
10.1016/j.csbj.2021.04.059
10.1016/j.csbj.2021.04.059
10.3389/fphar.2021.676239
10.3389/fphar.2021.676239 · doi-reference
10.1021/acschemneuro.9b00147
10.1021/acschemneuro.9b00147 · doi-reference
SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration
10.1016/j.bbrc.2021.03.100 · doi-reference
10.1038/s43588-020-00007-6
10.1038/s43588-020-00007-6 · doi-reference
10.1016/s1471-4906(01)01870-1
10.1016/s1471-4906(01)01870-1 · doi-reference
10.1016/j.csbj.2021.06.037
10.1016/j.csbj.2021.06.037 · doi-reference
COVID-19 and Alzheimer's disease: how one crisis worsens the other
10.1186/s40035-021-00237-2 · doi-reference
10.1016/j.ejmech.2020.112787
10.1016/j.ejmech.2020.112787 · doi-reference
Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects
10.1007/s00702-018-1876-2 · doi-reference
The use of multiscale molecular simulations in understanding a relationship between the structure and function of biological systems of the brain: The application to monoamine oxidase enzymes
10.3389/fnins.2016.00327 · doi-reference
10.1007/s12035-015-9284-1
10.1007/s12035-015-9284-1 · doi-reference
Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology
10.1186/1471-2202-8-73 · doi-reference
The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition
10.1111/j.1742-4658.2011.08386.x · doi-reference
10.1093/nar/gky473
10.1093/nar/gky473 · doi-reference
Dopamine autoxidation is controlled by acidic pH
10.3389/fnmol.2018.00467 · doi-reference
How important is the use of cocaine and amphetamines in the development of Parkinson disease? A computational study
10.1007/s12640-019-00149-0 · doi-reference
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration
10.1007/bf01246964 · doi-reference
Questions in the Chemical Enzymology of MAO
10.3390/chemistry3030069 · doi-reference
Exposing the Interplay Between Enzyme Turnover, Protein Dynamics, and the Membrane Environment in Monoamine Oxidase B
10.1021/acs.biochem.9b00213 · doi-reference
10.1002/minf.201100135
10.1002/minf.201100135 · doi-reference
10.1021/acs.jpclett.1c01415
10.1021/acs.jpclett.1c01415 · doi-reference
10.1038/s41422-021-00496-8
10.1038/s41422-021-00496-8 · doi-reference
10.1038/s41586-021-03402-9
10.1038/s41586-021-03402-9 · doi-reference
10.1016/j.meegid.2021.104773
10.1016/j.meegid.2021.104773 · doi-reference
10.1038/s41401-020-0485-4
10.1038/s41401-020-0485-4 · doi-reference
10.1101/2021.01.25.428190
10.1101/2021.01.25.428190 · doi-reference
10.1021/acs.jpcb.0c11321
10.1021/acs.jpcb.0c11321 · doi-reference
10.1016/j.csbj.2021.07.026
10.1016/j.csbj.2021.07.026 · doi-reference
10.1016/j.cmi.2021.05.022
10.1016/j.cmi.2021.05.022 · doi-reference
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
10.1016/s1473-3099(21)00262-0 · doi-reference
10.1021/acs.jpclett.1c03441
10.1021/acs.jpclett.1c03441 · doi-reference
10.1039/d0cs01065k
10.1039/d0cs01065k · doi-reference
In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
10.1038/s41598-021-92388-5 · doi-reference
10.1073/pnas.2008209117
10.1073/pnas.2008209117 · doi-reference